Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
A. Badros, Dianna S. Howard, Barry R. Meisenberg, Donna E. Reece, David H. Vesole, Joanne Filicko-O'Hara, Jasleen K Randhawa, Neal Flomenberg, Parameswaran Hari, Aaron P. Rapoport, Gordon L. Phillips
Publikováno v:
Bone Marrow Transplantation. 54:293-299
The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m2 (MEL 200). Higher doses of melphalan 220–260 mg/m2, although relatively well tolerated, have not shown significant improvement
Autor:
Ashkan Emadi, E Binder, N C Porter, Madhurima Koka, Zeba N. Singh, Noa G. Holtzman, Aaron P. Rapoport, F El Chaer
Publikováno v:
Bone marrow transplantation. 52(11)
Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL
Autor:
Ivana Gojo, G. Tricot, Ashraf Badros, Barry Meisenberg, Meyer R. Heyman, R Hakimian, G L Phillips, Kathleen Ruehle, Gorgun Akpek, T Withers, Bashi Ratterree, H Mannuel, Aaron P. Rapoport, Javier Bolaños-Meade, Sabrina Natt, E Kiggundu, C Sarkodee-Adoo, Robert G. Fenton, Naoko Takebe, Chuanfa Guo
Publikováno v:
Bone Marrow Transplantation. 34:883-890
Relapse remains a major cause of treatment failure after autotransplantation (auto-PBSCT) for Hodgkin's disease (HD). The administration of non-crossresistant therapies during the post-transplant period may delay or prevent relapse. We prospectively
Autor:
Timothy Chen, Guido Tricot, Clarence Sarkodee-Adoo, Richard J.H. Smith, Kathleen Ruehle, Stanley R. Frankel, Michele Cottler-Fox, B Mookerjee, L Kight, A. Badros, A Kennedy, Naoko Takebe, A. Fassas, S Chambers, M Jacobs, Meyer R. Heyman, R Hudes, M MacFadden, Aaron P. Rapoport, Barry Meisenberg, Robert G. Fenton, G Phillips
Publikováno v:
Bone Marrow Transplantation
Disease relapse occurs in 50% or more of patients who are autografted for relapsed or refractory lymphoma (NHL) or Hodgkin's disease (HD). The administration of non-cross-resistant therapies during the post-transplant phase could possibly control res
Autor:
Michele Cottler-Fox, I Gojo, Guido Tricot, JC Papadimitriou, Athanasios Fassas, Barry Meisenberg, Aaron P. Rapoport
Publikováno v:
Bone Marrow Transplantation. 28:399-403
We report on three patients with multiple myeloma who developed drug-induced pneumonitis 1-2(1/2) months following maintenance (post autologous transplantation) chemotherapy with CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) and 6-20 m
Autor:
T. Linder, Reggie E. Duerst, L. M. Zwetsch, WA Silverman, B McKenna, Lucy A. Wedow, Charles H. Packman, Jane L. Liesveld, Jacob M. Rowe, Camille N. Abboud, Louis S. Constine, SB Swift, Aaron P. Rapoport, John F. DiPersio
Publikováno v:
Bone Marrow Transplantation. 24:511-516
Unrelated donor marrow transplantation is associated with an increased incidence of graft-versus-host disease (GVHD) compared with sibling donor transplants. Forty-one patients undergoing unrelated donor transplants were treated with a GVHD prophylax
Autor:
Richard F. Raubertas, Camille N. Abboud, Louis S. Constine, Reggie E. Duerst, Shirley Eberly, Charles H. Packman, Flesher Wr, Martin Ba, Aaron P. Rapoport, John F. DiPersio, Jane L. Liesveld, Lifton R, Peter A. Kouides, Jacob M. Rowe
Publikováno v:
Bone Marrow Transplantation. 19:883-890
One hundred and thirty-six patients autografted for relapsed or refractory non-Hodgkin's lymphoma (NHL) were evaluated to assess long-term event-free survival and to identify important prognostic factors. High-dose therapy consisted primarily of carm
Autor:
Kathleen Ruehle, Chuanfa Guo, G. L. Philips, Ivana Gojo, C. Sarkodee-Adoo, Michele Cottler-Fox, Ming Tan, Guido J Tricot, A. Murthy, Meyer R. Heyman, Barry Meisenberg, Robert G. Fenton, Aaron P. Rapoport, T. French, A. Fassas, Naoko Takebe
Publikováno v:
Bone marrow transplantation. 37(1)
Although high-dose therapy and autologous stem cell transplant (ASCT) is superior to conventional chemotherapy for treatment of myeloma, most patients relapse and the time to relapse depends upon the initial prognostic factors. The administration of
Autor:
Michele Cottler-Fox, A Fassas, Ivana Gojo, Guido J Tricot, Barry Meisenberg, Aaron P. Rapoport, Chuanfa Guo, Meyer R. Heyman, Naoko Takebe, C. Sarkodee-Adoo
Publikováno v:
Bone marrow transplantation. 34(1)
The purpose of the study was to examine the yield of CD34(+) cells, response rates, and toxicity of high-dose cyclophosphamide with or without etoposide in patients with multiple myeloma. In total, 77 myeloma patients received either cyclophosphamide
Autor:
Clarence Sarkodee-Adoo, John L. Wagner, Joanne Filicko, Val R. Adams, Naoko Takebe, V. P. Johnson, Aaron P. Rapoport, D. E. Reece, Barry Meisenberg, Bijoyesh Mookerjee, Robert G. Fenton, J. Brunner, K. W. Marshall, A. Badros, Gordon L. Phillips, A. Kniska, Neal Flomenberg, G. A. Hale, Dianna S. Howard, David H. Vesole, D. L. Grosso, R. Nath
Publikováno v:
Bone marrow transplantation. 33(8)
High-dose chemotherapy using melphalan (HDMEL) is an important component of many conditioning regimens that are given before autologous hematopoietic stem cell transplantation (AHSCT). In contrast to the situation in myeloma, and to a lesser degree a